<analysis>
No adversary threats were submitted this month, so only the six actions are assessed.

**Action 1: meta-scorer ablation.** Four things have to happen:
- **Schedule.** Moving a Q4 ablation forward to October 6–24 needs the compute lead to grant a second reserved window while the CI-4 sweeps intensify. Last month's 7-day window was granted reluctantly.
- **Decision rule.** Post-training must co-sign a rule that makes the term a default in the CI-4 recipe. That is a much stronger commitment than the earlier shadow-arm rule, which was itself resisted. The likeliest outcome is a co-signed measurement plan with the "default term" wording softened to "will consider."
- **METR consent.** The honeypots are METR's. Using them, and fresh unseen subsets, to score Anthropic's training needs METR to agree. METR has guarded its independence before and may insist on running the scoring itself or limit how often it can be used.
- **Timing.** Finishing all seeds by October 24 is tight given the queueing history.

The scientific result is a separate draw from nature. My base rate that the meta-scorer lifts honeypot capture reduction from 13% to 25% or more is about 25–30%, whatever happens to the action. Overall, the action is ambitious and has several blockers.

**Action 2: tiered monitor enforcement.** Asking reviewers to approve only categories at or below 2% false positives is a realistic way to win partial approval. The Hugging Face-class categories are narrow and high-signal, so low false-positive rates there are plausible. Risks:
- Reviewers may want another validation cycle.
- Per-category sample sizes may be too small to support 2% claims.
- The router design (screener plus a 20% random sample) may still exceed the cost cap.

**Action 3: cross-lab measurement including Fable 6.1.** Third parties can already measure a public product. What matters is leadership's posture: they have declined point estimates three times, and they may ask for pre-publication review or quietly discourage the measurement. METR is already running the Q4 comparison, so adding Fable 6.1 is low-cost for them. The proposed rate-limit "patch" for UK AISI raises a terms-of-service question. AISI has its own arrangement with Google DeepMind and may decline anything that looks like a workaround. Even if all of this goes well, a joint table within Q4 is unlikely to publish this month.

**Action 4: Antwerp defender package.** Publishing detection rules is within Anthropic's control. The other parts depend on outside bodies:
- **CERT-EU/ENISA co-branding.** EU agencies move slowly and are cautious about endorsing a US vendor. Acknowledgement is likelier than co-branding.
- **Consultation filing.** Easy.
- **NENA walkthrough.** Plausible.
- **APCO.** Uncertain.
- **Hospital drills to 35%.** Moderate.
- **Export-review carve-out.** This is a bureaucratic queue, so the separate release is unlikely within the month.

**Action 5: daylight on policy work.** The senator's agreement to publication is plausible. Comms has already said "Q4," so bringing the aggregate count forward is a modest ask, though the live Politico story could make comms either more or less willing. A default attribution header needs product-policy and counsel approval. Watering down is likely.

**Action 6: benefits.** These are mostly routine extensions. The murine outcome is a nature draw: roughly 40–50% of leads at this stage show meaningful efficacy in a thigh model. Results probably arrive in November, so not this month. Approaches to CARB-X and GARDP are feasible, but funding decisions take months. Onboarding the three towns is routine, and designing the Cellwise validation is straightforward.
</analysis>

<action_odds>
Action 1 [Meta-scorer ablation + co-signed rule]: P(failure) 55%. Reason: Compute contention with the CI-4 sweeps, post-training's resistance to a default-inclusion rule, and the need for METR's explicit consent to use its honeypots all stack up. The scientific result is drawn separately, at a base rate of about 25–30%.

Action 2 [Tiered monitor enforcement]: P(failure) 40%. Reason: Approving only a subset is the realistic path through sign-off. However, the per-category false-positive evidence may be thin, and the cost cap may limit the router.

Action 3 [Cross-lab capture incl. Fable 6.1]: P(failure) 40%. Reason: METR and Toronto can measure a public model cheaply. Leadership may still push for pre-review, and UK AISI is likely to decline the rate-limit workaround. The joint table is not due this month.

Action 4 [Antwerp defender package + EU filing]: P(failure) 35%. Reason: Publishing the rules and filing with the consultation are under Anthropic's control. EU co-branding, the export carve-out and the drill target are slower and uncertain.

Action 5 [Attributed Colorado analysis + aggregate count]: P(failure) 45%. Reason: Senator consent is plausible, but comms and counsel have refused related requests before, and the default attribution header needs policy approval.

Action 6 [ANT-17 support, worker program, Cellwise validation]: P(failure) 25%. Reason: These are routine extensions through existing partners. Funder commitments and in vivo outcomes depend on outside decision-makers and on nature, not on whether the action succeeds.
</action_odds>
